Ligand Pharmaceuticals Inc (LGND)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $318.78
- As of
Kresmion compiles this page from LGND's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
LIGAND PHARMACEUTICALS INC (LGND): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-24.
See the full LGND dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for LGND on one page. Preview it with sample data, then open it live with a free account.
Preview the LGND dossierActive events for LGND
- high13F: funds added
3 tracked funds increased LGND this 2026Q2, institutional consensus
- mediumEarnings above estimates
Q2-2026: Beat consensus by 26.2%, EPS $2.37 vs $1.878 estimate
- high13F: large reduction
CITADEL ADVISORS LLC cut 51% of LGND (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +186% to LGND (2026Q2)
- high13F: large reduction
Point72 Asset Management, L.P. cut 95% of LGND (2026Q2)
FREE, NO ACCOUNT
Every event on LGND, as it fires
You are seeing 5 of 16 events recorded on LGND since 2026-06-16.
The five above landed across 3 days. The other 11 were recorded on 3 other days. 9 of the 16 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in LGND (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 53220K504 · 2026Q2 | $17.9M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 53220K504 · 2026Q2 | $6M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 53220K504 · 2026Q2 | $1.3M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, LGND
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
LGND against its peers
LGND's operating margin of 15.3% ranks in the 82nd percentile of 13 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-03-31.
| Metric | LGND | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 268M USD | 264M USD | 53 | 15 |
| Gross margin | n/a | 89.7% | n/a | 5 |
| Operating margin | 15.3% | -40.4% | 82 | 13 |
| Net margin | 46.4% | -40.4% | 96 | 13 |
| Return on equity | 12.2% | -36.0% | 93 | 22 |
| P / E | 52.0x | n/a | n/a | 2 |
Peers (24): ORKA, RYTM, CNTA.D, KOD, IMVT, IOVA, MANE, BLTE, GRAL, CGON, COGT, MIRM, IONS, ALKS, ERAS, SRRK, PTCT, APLS.D, CRSP, ABVX, DFTX, PRAX, TVTX, ARWR. Left out: BCHMY (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (LGND: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow LGND on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to LGND for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.